Acedol SR Tablet (Sustained Release) 200 mg

Acedol SR Tablet (Sustained Release) is a premium NSAID medication containing 200 mg Aceclofenac, manufactured by Concord Pharmaceuticals Ltd. This sustained-release tablet offers prolonged pain relief for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and dental/injury-related inflammation. Priced at ৳7.00 per unit (with a strip price of ৳70.00), it ensures affordability for chronic conditions.

As a cyclooxygenase inhibitor, Aceclofenac blocks prostaglandin synthesis, addressing pain and swelling effectively. The sustained-release formula allows once-daily dosing (200 mg), enhancing patient compliance. Always consult a physician for dosage adjustments or alternative regimens like film-coated tablets (100 mg twice daily).

Common side effects include mild digestive discomfort, nausea, or skin rashes. Avoid combining with diuretics, anticoagulants, or lithium without medical supervision. Store in dry, cool areas away from children. Pregnant/lactating women should use it cautiously after evaluating benefit-risk ratios.

Explore other Aceclofenac brands like Acedol 100 mg for varied strengths. Concord Pharmaceuticals maintains strict quality standards in producing this 200 mg NSAID tablet, making Acedol SR a trusted choice for long-term inflammatory management in Bangladesh.

Adults: 200 mg once daily for sustained-release tablets. Immediate-release: 100 mg twice daily. Dose adjustment needed in hepatic/renal impairment. Take after meals. Avoid prolonged use beyond 10 days without medical supervision.

Acedol SR is a non-steroidal drug with anti-inflammatory and analgesic properties. It is a potent inhibitor of the enzyme cyclooxygenase, which is involved in the production of prostaglandin. After oral administration, it is rapidly and completely absorbed an unchanged drug.

Avoid during pregnancy (especially third trimester). Not safe in lactation – excreted in breast milk. Consider alternative therapies.

Monitor renal function during long-term use. Use proton pump inhibitors in patients with gastric ulcer history. Use lowest effective dose in cardiovascular risk patients.

Pediatric safety unknown. Reduce dose in elderly. 50% dose reduction in renal/hepatic impairment. Not recommended for dialysis patients.